HTG Announces Completion Of IVD Development And Supply Agreement With Illumina, Inc.

TUCSON, AZ--(Marketwired - October 30, 2014) -

HTG Molecular Diagnostics, Inc. (HTG), a provider of instruments and reagents for molecular profiling applications, today announced that it entered into an agreement with Illumina, Inc. (NASDAQ: ILMN), under which HTG will have the right to develop certain in-vitro diagnostic (IVD) test kits that utilize Illumina sequencing technology.

“We believe pairing the HTG EdgeSeq chemistry and automation platform with Illumina sequencing technology is a powerful combination for developing diagnostic panels that enables local molecular labs to adopt sequencing for routine clinical use,” stated TJ Johnson, HTG CEO. “Our HTG EdgeSeq Research Use Only products that utilize Illumina sequencers have demonstrated outstanding performance in reproducibility and low sample requirement. These factors convinced us that this is the best direction to go in pursuing our IVD pipeline.”

About HTG:

HTG Molecular Diagnostics, Inc. provides a novel technology platform that allows for precise, efficient molecular profiling of a wide variety of samples including formalin-fixed paraffin-embedded tissue. Our automated HTG Edge platform is designed to quickly and simultaneously profile thousands of clinically relevant molecular targets from samples a fraction of the size required by current technologies. The HTG Edge platform provides significant workflow and performance advantages in molecular profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. We developed our platform to facilitate the routine use of complex molecular profiling for molecular labs from research to the clinic.